Dry eye disease - bloodshot eye close-up

2026 Strategic Vision

Healing the
Source of Pain

Our RuCIA platform leverages AI molecular design to predict membrane-protein (ion channel) selectivity, developing non-opioid pain and dry eye therapeutics (FDA Phase 2). 70% faster development timeline with 100% target selectivity.

Explore Pipeline Our Science

Scroll

Core Technology

Membrane Target Drug Discovery

We develop membrane-targeted therapeutics using electrophysiology-based ion channel activity measurement. Through patch clamp and high-throughput electrophysiology validation, we discover selective modulators of ion channels such as TRPV1, verifying efficacy and safety of non-opioid pain and dry eye (sensory disease) treatments with real data.

Electrophysiology

Patch Clamp HT Validation

Membrane Target

Selective Ion Channel Modulation

$94B

Global Chronic Pain by 2030

RCI002 Dual Target Peptide Mechanism of Action — TRPV1 & MOR Membrane Target

Therapeutic Programs

The Pipeline

Pipeline Details →

RCI001US FDA Phase 2

Dry Eye Disease

Anti-inflammatory/antioxidant mechanism targeting Rac1 via TRPV1 downstream signal modulation. Overcomes steroid limitations with rapid tear secretion and corneal wound healing.

Progress75%

Target: TRPV1-Rac1Phase 2 IND Q2 2026

RCI002Pre-clinical / IND

Non-Opioid Pain

MOR biased dual-target non-opioid analgesic simultaneously modulating TRPV1 and MOR. Zero hyperthermia, long-lasting pain relief without addiction or tolerance risk.

Progress40%

Target: TRPV1-MOR Biased DualTox Study 3Q 2026

Partners & Recognition